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Abstract
Background
Genetic and environmental factors contribute to the pathophysiology of irritable bowel syn-
drome (IBS). In particular, early adverse life events (EALs) and the catecholaminergic sys-
tem have been implicated.
Aims
To investigate whether catecholaminergic SNPs with or without interacting with EALs are
associated with: 1) a diagnosis of IBS, 2) IBS symptoms and 3) morphological alterations in
brain regions associated with somatosensory, viscerosensory, and interoceptive
processes.
Methods
In 277 IBS and 382 healthy control subjects (HCs), 11 SNPs in genes of the catecholamin-
ergic signaling pathway were genotyped. A subset (121 IBS, 209 HCs) underwent structural
brain imaging (magnetic resonance imaging [MRI]). Logistic and linear regressions evalu-
ated each SNP separately and their interactions with EALs in predicting IBS and GI symp-
tom severity, respectively. General linear models determined grey matter (GM) alterations
from the SNPs and EALs that were predictive of IBS.
PLOS ONE | DOI:10.1371/journal.pone.0135910 August 19, 2015 1 / 17
OPEN ACCESS
Citation: Orand A, Gupta A, Shih W, Presson AP,
Hammer C, Niesler B, et al. (2015)
Catecholaminergic Gene Polymorphisms Are
Associated with GI Symptoms and Morphological
Brain Changes in Irritable Bowel Syndrome. PLoS
ONE 10(8): e0135910. doi:10.1371/journal.
pone.0135910
Editor: Monica Uddin, University of Illinois-Urbana
Champaign, UNITED STATES
Received: November 10, 2014
Accepted: July 28, 2015
Published: August 19, 2015
Copyright: © 2015 Orand et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The data files are
available from the Figshare database (accession
number: http://dx.doi.org/10.6084/m9.figshare.
1501512).
Funding: The work was supported by P50
DK064539 (EAM), RO1 DK048351 (EAM), P30
DK041301, Medical Faculty University of Heidelberg
(BN).
Competing Interests: The authors have declared
that no competing interests exist.
Results
1) Diagnosis: There were no statistically significant associations between the SNPs and
IBS status with or without the interaction with EAL after adjusting for multiple comparisons.
2) Symptoms: GI symptom severity was associated with ADRA1D rs1556832 (P = 0.010).
3) Brain morphometry: In IBS, the homozygous genotype of the major ADRA1D allele was
associated with GM increases in somatosensory regions (FDR q = 0.022), left precentral
gyrus (q = 0.045), and right hippocampus (q = 0.009). In individuals with increasing sexual
abuse scores, the ADRAβ2 SNP was associated with GM changes in the left posterior
insula (q = 0.004) and left putamen volume (q = 0.029).
Conclusion
In IBS, catecholaminergic SNPs are associated with symptom severity and morphological
changes in brain regions concerned with sensory processing and modulation and affect reg-
ulation. Thus, certain adrenergic receptor genes may facilitate or worsen IBS symptoms.
Introduction
Irritable bowel syndrome (IBS) affects approximately 10.5% of the population (6.6% of men
and 14.0% of women).[1] As currently defined, IBS likely represents a heterogeneous group of
disorders presenting with a similar symptom pattern, which is characterized by abdominal
pain, altered bowels habits and gastrointestinal (GI) symptom-specific anxiety.[2] Several stud-
ies suggest an interaction between genetic and environmental factors (including early adverse
life events [EALs]) in the development of altered brain-gut interactions in IBS.[3–6]
Single nucleotide polymorphisms (SNPs) residing in genes of catecholaminergic signaling
systems (including genes encoding adrenergic receptors and catechol-o-methyltransferase
[COMT]) have been implicated in the pathophysiology of chronic pain disorders.[7–9] COMT
has broad biological functions, including the metabolism of both catecholamines (epinephrine,
norepinephrine, and dopamine) and enkephalins.[10] Polymorphisms in the COMT gene can
influence catecholamine and enkephalin levels, which have been associated with dysregulation
of pain modulatory systems in visceral pain.[3,8] SNPs in adrenergic receptors have also been
implicated in the pathophysiology of IBS and chronic pain.[7,11] In a study of five adrenergic
receptor genes, genotype frequences of SNPs residing in the alpha adrenergic-β2 (ADRAβ2)
and alpha adrenergic-1D (ADRA1D) receptor genes differed significantly between patients
with interstitial cystitis, also known as painful bladder syndrome (which commonly coexists
with IBS) and healthy controls.[9] ADRAβ2 polymorphisms were found to predict temporo-
mandibular disorder status in 386 healthy individuals.[7] These studies show that while cate-
cholaminergic SNPs alone do not cause IBS or any other chronic pain disorders, they may play
a role by interacting with other genes and environmental factors such as EALs.
Several recent reports have demonstrated neuroplastic grey and white matter differences
between IBS patients and healthy control subjects.[12–15] For example, IBS patients showed
both smaller and larger regional grey matter volumes (GMV)[12] and increased cortical thick-
ness (CT)[13], in particular in regions and networks involved in sensory processing (somato-
sensory, precentral and postcentral gyrus; viscerosensory, posterior insula), and decreased CT
in regions associated with affect regulation (e.g., hippocampus, subgenual anterior cingulate
cortex [sgACC]). Other studies have shown that grey matter (GM) volume alterations in pain
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and interoceptive regions (insula subregions) correlated with visceral sensitivity[15] and GI
symptom severity.[14] It is currently not known if the observed brain changes are a conse-
quence of chronic pain, or if they are genetically/environmentally determined vulnerability fac-
tors that increase the likelihood of developing persistent symptoms in response to certain
triggering events, such as gastroenteric infections or injuries.[14–16] Several molecular mecha-
nisms (some related to chronic stress) including neuronal or glial cell loss, reduction in the
density of dendritic spines, and neurogenesis have been proposed to explain some of the neuro-
plastic changes.[13–15]
Although studies have investigated the relationship between catecholaminergic SNPs and
some chronic pain disorders, the interactions between these SNPs, EALs, and resultant changes
in brain structures in IBS patients have not been reported. The catecholaminergic SNPs evalu-
ated in this study were chosen based on an extensive review of the literature (Table 1). We
searched specifically for SNPs associated with IBS and comorbid conditions in which studies
suggest that autonomic nervous system dysregulation plays a role in the pathophysiology of
the disease process. [8,17–19] Our aim was to investigate whether catecholaminergic SNPs
with or without interacting with EALs are associated with: 1) a diagnosis of IBS, 2) IBS symp-
toms and 3) morphological alterations in brain regions associated with somatosensory, viscero-
sensory, and interoceptive processes.
Materials and Methods
Study Subjects and Recruitment
IBS patients and healthy controls (HCs) were primarily recruited from community advertise-
ments although some patients were recruited from a functional bowel disorders clinic at a uni-
versity hospital setting. Subjects were between 18–55 years of age and underwent a medical
history and physical examination by gastroenterologist or nurse practitioner with expertise in
IBS. The diagnosis of IBS and bowel habit subtyping was determined by Rome III criteria,[20]
the absence of other chronic GI conditions, and by a clinician with expertise in IBS. Demo-
graphic information including age, gender, body mass index (BMI), and race and ethnicity of
subjects was collected. Race and ethnicity was determined using the NIH policy guidelines for
collecting and presenting data on race and ethnicity for all NIH research studies.[21] Exclusion
criteria comprised pregnancy, substance abuse, abdominal surgery, tobacco dependence
(smoked half a package of cigarettes or more daily), psychiatric illness, and extreme strenuous
exercise (exercised one hour or more per day). HCs had no history of IBS, other chronic pain
disorders, or psychiatric illnesses, and were not taking beta-adrenergic blockers or centrally
acting drugs (antidepressants, anxiolytics, narcotics).
All subjects were compensated for participating in the study, and written informed consent
was obtained from all subjects. The study was approved by the University of California Los
Table 1. Catecholaminergic SNPs.
Gene SNPs Name Function
COMT rs4680 (Val158Met), rs6269, rs174697 Catechol-o-
methyltransferase
Degrades catecholamines (Norepinephrine, Epinephrine,
Dopamine)
ADRAβ2 rs1432622, rs2400707, rs1042717,
rs1042713
Adrenergic β2 receptor Mediates sympathetic activity
ADRA1D rs1556832, rs946188 Adrenergic 1D receptor Mediates sympathetic activity
ANKK1 rs1800497 DRD2/ANKK1- Taq1A Mediates dopamine activity
DRD3 rs6280 D3 dopamine receptor Mediates dopamine activity
doi:10.1371/journal.pone.0135910.t001
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Angeles (UCLA) Institutional Review Board and was conducted in accordance with the institu-
tional guidelines regulating human subjects research.
SymptomMeasures
A bowel symptom questionnaire was used to assess the presence and severity of IBS symptoms
(abdominal pain, bloating, usual and overall IBS symptom severity) and determine fulfillment
of the Rome III diagnostic criteria.[22] Severity of abdominal pain, IBS symptoms, and sensa-
tion of bloating during the past week were assessed on a scale from 0 (no pain) to 20 (most
intense pain imaginable).[23] Usual IBS symptom severity was ranked on a 5-point scale,
which included: none, mild, moderate, severe or very severe symptoms.[23] EALs were mea-
sured using the Early Trauma Inventory- Short Form Self Report (ETI-SR).[24] The ETI-SR
questionnaire assesses 27 individual items within 4 EAL domains: general trauma (11 ques-
tions), physical trauma (5 questions), emotional trauma (5 questions) and sexual abuse (6
questions). Items scored “yes” = 1 point and “no” = 0 points. The total score ranges from 0–27,
and has been used in IBS to measure number of EAL events.[23]
Other on-GI clinical traits were assessed using the following scales: current anxiety and
depression symptoms (Hospital Anxiety and Depression Scale [HAD]),[25] GI-symptom spe-
cific anxiety (Visceral Sensitivity Index [VSI]),[26] somatic symptoms (Patient Health Ques-
tionnaire [PHQ-15]), [27] quality of life- short form (SF-12-physical and mental), [28] trait
anxiety, [29] bowel symptom questionnaire (BSQ), [30] and personality inventory (NEO
scales). [31] In addition, all the subjects had previously undergone a structured psychiatric
interview (MINI) to measure past or current psychiatric illness.[32,33]
DNA Collection
DNA extracted from salivary samples of IBS patients and HCs was processed and assessed
by the UCLA Biological Samples Processing Core using the Autopure LS Nucleic Acid Puri-
fication instrument (Gentra Systems, Inc., Minneapolis, MN.) The COMT polymorphism
(rs174697) was genotyped using a 50 nuclease assay to discriminate between the two alleles
A/G (Taqman SNP Genotyping Assay C_2255328_10, Applied Biosystems Inc.). Polymerase
chain reactions were performed using 5-μL reaction volumes in 384-well plates with 5 ng of
DNA. The standard protocol provided with the kit was followed. End point reads of fluores-
cence levels were obtained with an ABI 7900HT Sequence Detection System. The SNPType
genotyping was done on the other 10 SNPs using the Fluidigm Biomark system. First, 10–60 ng
of DNA was pre amplified using Qiagen Multiple PCR master mix. This was then diluted and
used for amplification as starting material. Next, the samples and assays were loaded onto GT
9696 Dynamic array and processed per Fluidigm protocol. The assays used were designed
using Fluidigm’s proprietary technology. The genotyping calls were made using Fluidigm SNP
genotyping software. The SNPs rs4680 and rs6280 were genotyped with the KASP genotyping
system (KBiosciences, Ltd, Hoddesdon, UK) as recommended by the manufacturer using cus-
tomized assays as outlined previously.[34]
Brain imaging. Structural brain images were obtained from a subset of IBS patients and
HCs in whom DNA samples were collected.
MRI structural data acquisition. High resolution structural images were acquired with a
magnetization-prepared rapid acquisition gradient echo (MP-RAGE) sequence with the fol-
lowing parameters: repetition time (TR) = 2200ms, echo time (TE) = 3.26ms, slice
thickness = 1mm, 176 slices, 256 x 256 voxel matrices, and 1.0×1.0×1.0mm voxel size.
Cortical Thickness (CT) and Grey Matter Volume (GMV). The University of Southern
California Laboratory of Neuroimaging pipeline (http://pipeline.loni.usc.edu/), a graphical
Catecholaminergic Polymorphisms in IBS
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workflow environment was utilized for image preprocessing and CT and GMV analyses. All
structural scans were first converted from DICOM to NIFTI, a format that could be analyzed,
including intensity inhomogeneity correction,[35] skull-stripping,[36,37] and cortical surface
modeling.[38] Gray matter thickness and volume were estimated using a well-validated
method[39] implemented in FreeSurfer 4.0[38] (available free to the public, http://surfer.nmr.
mgh.harvard.edu/fswiki and http://ucla.in/xSQPqT). The obtained CT and GMVmaps were
registered to International Consortium for Brain Mapping (ICBM) brain surface and then ver-
tex-wise correspondences were established between all cortical surface models using a confor-
mal metric optimization method.[40] In order to increase statistical power, an 8 mm heat
kernel[41] was applied to smooth the realigned thickness and volume maps. Total brain vol-
ume (TBV) values were also obtained from the same pipeline. Data is available on our Pain
website (http://painrepository.org/) as part of the Pain and Interoception Network (PAIN)
repository.
Statistical Analysis
Genetic analysis. Eleven catecholaminergic SNPs residing in five genes were genotyped
(Table 1). Hardy–Weinberg equilibrium and three different genetic models (additive, domi-
nant, and recessive) were tested for each SNP. The dominant genetic model (one or more cop-
ies of the minor allele vs. no copies) was found to be the most statistically significant in
unadjusted comparisons with IBS status, and thus this model was utilized for all SNPs to focus
downstream analyses. Individual logistic regressions were used to predict the odds of IBS status
from each SNP while controlling for race and sex. We also evaluated the effect of the interac-
tions between EAL and each SNP in predicting IBS status. As an exploratory analysis, we also
repeated this model controlling for HAD anxiety and depression scores. Any EAL x SNP inter-
actions that were significant were further characterized by running separate logistic regression
models within each genotype group (homozygous major and heterozygous/homozygous
minor). Significance for the primary analysis was p<0.002 to adjust for analyzing ETI-SF
(EAL) total score and the four subdomains and the five genes. We did not control for multiple
comparisons in our secondary aim (the effect of the catecholaminergic SNPs on GI symptoms)
because it was an exploratory analysis. The 0.05 significance level was used to define important
interactions for the brain imaging analysis.
We also conducted exploratory analyses comparing an additional 26 clinical traits (which
included GI symptoms and non-GI symptoms) with each SNP within the IBS group. Explor-
atory factor analysis (EFA) was used to mitigate multiple testing for this explorative analysis by
reducing the dimensionality of the 26 clinical traits down to a few representative latent factors.
A scree plot was used to estimate the number of factors. The factors were then extracted using
principal-component analysis, and we determined the optimal configuration of items on fac-
tors using a varimax rotation. Finally, we tested each of the latent factors with each SNP in lin-
ear regression models that controlled for race and sex. Significance was defined by p<0.05. All
statistical analyses were performed using R version 3.0.2 (http://cran.r-project.org/) and all
tests were two-tailed.
Brain imaging analysis. To test the specific hypotheses, linear contrast analysis within the
framework of the general linear models (GLM) were constructed to examine the main and
interactive effects of genetic variation (in the SNPs found to predict IBS and correlate with GI
symptoms) with EALs on the CT and GMV of specific brain regions, controlling for race, sex
and total brain volume (TBV). Linear contrast analyses specified to test how IBS compared to
HCs. A GLM was chosen for these analyses in order to describe a large number of responses
(morphological measures) as a function of first early adverse life events and then GI symptoms.
Catecholaminergic Polymorphisms in IBS
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An exploratory analysis covariate analysis with depression and anxiety scores was conducted
in the GLMmodel specified above, in order to determine if these mood measurements could
be confounding factors. Correlations were also conducted between GM alterations and IBS spe-
cific symptoms. Twenty specific brain regions selected were based on previously published
papers where significant differences between IBS and HCs were found (a summary of these
brain regions and their functions has been provided in (Table 2).[12,13] Corrections for multi-
ple brain regions of interest (ROI) comparisons were made using the false discovery rate
(FDR), where a FDR q<0.05 was considered significant.[42,43]
Results
Baseline Clinical Characteristics
There were 659 subjects who participated in the study. This group was comprised of 277 IBS
patients (mean age 36.4 yrs, 75.2% women) and 382 HCs (mean age 30.3 yrs, 73.2% women).
Of these 659 subjects, a subset of 330 right-handed individuals (121 [43.7%] IBS, 209 [54.7%]
HCs) completed structural MRI scans. The baseline clinical characteristics of the larger group
and subset who underwent brain imaging are summarized in Table 3. In both the larger
dataset and brain imaging subset, the IBS patients had significantly higher scores on the
Hospital Anxiety and Depression Scale (HAD), ETI-SR (EALs) and visceral sensitivity index
(VSI) than HCs. In the larger dataset, the IBS patients also had a significantly higher mean age
and ETI-SR sexual abuse score. Except for one IBS subject on chronic low dose amitriptyline
(50 mg daily), no other patients were taking centrally acting medications.
Association of Catecholaminergic SNPs and IBS Diagnosis
There was no significant difference in genotype frequencies between IBS and HCs for the
11 SNPs in the overall group (Table 4) and in the subset with brain imaging (S1 Table). Fur-
thermore, there were no significant SNP and EAL interactions after correcting for multiple
comparisons. However, there were two SNP and EAL interaction that had uncorrected p-val-
ues<0.05 and were assessed in the brain imaging analysis (see below). Individuals who were
homozygous carriers of the ADRAβ2 rs1042717 major G allele were associated with increased
likelihood of having IBS with increasing sexual abuse score as compared to individuals who
Table 2. Summary of brain regions used in the analyses and their associated functions.
Brain Regions Associated Function
Insula (anterior insula [aINS] and mid insula [mINS]) Interoceptive integration, and viscerosensory
processing
Posterior Insula (pINS) Primary viscerosensory cortex
Anterior Cingulate Cortex [ACC] (subgenual [sgACC],
pregenual [pgACC])
Affect regulation
Anterior Mid Cingulate Cortex (aMCC) Endogenous pain modulation
Postcentral Gyrus (PostCG) Sensory processing, integration and modulation
Precentral Gyrus (PreCG) Motor control
Amygdala (Amyg) Affect regulation, autonomic output, endogenous
pain modulation
Hippocampus (Hipp) Affect control, memory
Putamen Sensory processing, integration and modulation,
reward, and learning
Superior Frontal Gyrus (SFG) Cognitive modulation
Gyrus Rectus Cognitive modulation
Middle Orbital Gyrus (mOFG) Cognitive modulation
doi:10.1371/journal.pone.0135910.t002
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carried the minor A allele in a heterozygous or homozygous manner (odds ratios [OR]: 1.48
[95% CI 1.17–1.87] vs. 1.10 [0.92–1.32], p = 0.039) (Fig 1). Similarly, compared to the individu-
als who presented with a heterozygous or homozygous state of the minor A allele (i.e., had at
least one minor A allele) for COMT rs174697, individuals who carried the homozygous major
G allele (i.e., had both copies of the major G allele) had a higher likelihood of having IBS if they
had an increasing emotional abuse score (OR: 1.52 [1.33–1.74] vs. 1.14 [0.92–1.42], p = 0.041)
(Fig 2). After controlling for HAD anxiety and depression scores, the interactions between
EAL scores and ADRAβ2 rs1042717 and COMT rs174697 were not statistically significant.
Association of Catecholaminergic SNPs and Symptoms
Five latent factors were identified using factor analysis for the 26 clinical traits within the IBS
population. The latent factors were summarized as psychological traits, somatic symptoms,
Table 3. Clinical Characteristics of Subjects.
Genetics Dataset Brain Imaging Dataset
HCs (N = 381) IBS (N = 278) HCs (N = 205) IBS (N = 115)
Variable Mean (SD) Mean (SD) p-value Mean (SD) Mean (SD) p-value
Age (yrs.) 30.29 (10.68) 36.4 (12.38) <0.001 30.95 (11.12) 31.92 (10.2) 0.178
BMI (SD) 24.55 (4.7) 25.17 (5.01) 0.101 24.28 (4.31) 23.71 (3.99) 0.346
Female: N (%) 279 (73.22%) 209 (75.18%) 0.59 165 (80.49%) 85 (73.91%) 0.221
Race <0.001 0.002
Caucasian 154 (41.4%) 166 (61.5%) 82 (40.8%) 68 (60.2%)
Asian 106 (28.4%) 32 (11.9%) 66 (32.9%) 20(17.7%)
African American 56 (15.1%) 37 (13.7%) 29 (14.4%) 9 (8.0%)
Other/Mixed 56 (15.1%) 35 (12.9%) 24 (11.9%) 16 (14.1%)
HAD Anxiety (0–21) 3.35 (2.77) 7.35 (4.28) <0.001 3.18 (2.7) 6.49 (3.59) <0.001
HAD Depression (0–21) 1.32 (1.75) 3.83 (3.39) <0.001 1.36 (1.78) 3.00 (2.98) <0.001
VSI Score (0–90) 2.51 (5.07) 34.75 (16.35) <0.001 2.81 (5.24) 33.37 (14.76) <0.001
ETI General Trauma Score (0–11) 1.51 (1.67) 2.47 (2.18) <0.001 1.47 (1.52) 2.06 (1.77) 0.002
ETI Physical Score (0–5) 1.14 (1.43) 1.58 (1.60) <0.001 1.03 (1.34) 1.33 (1.45) 0.058
ETI Emotional Score (0–5) 0.71 (1.33) 1.58 (1.77) <0.001 0.68 (1.28) 1.39 (1.68) <0.001
ETI Sexual Score (0–6) 0.36 (0.96) 0.76 (1.53) <0.001 0.37 (0.97) 0.49 (1.14) 0.245
IBS Bowel Habit Subtype: N (%)
Constipation 62 (22.30%) 31 (26.96%)
Diarrhea 65 (23.38%) 24 (20.87%)
Mixed 138 (49.64%) 55 (47.83%)
Unspecified 13 (4.68%) 5 (4.35%)
BSQ Symptoms (SD)
Overall Severity (0–20) 10.17 (4.56) 10.67 (4.34)
Abdominal Pain (0–20) 9.34 (5.12) 9.77 (5.04)
Bloating (0–20) 11.00 (5.36) 12 (5.15)
Usual Severity of IBS (1–5) 3.13 (0.81) 3.11 (0.78)
Age of Onset of IBS (yrs) 20.15 (12.04) 19.39 (9.95)
Severity Duration (yrs.) 11.68 (11.2) 9.96 (8.5)
Abbreviations: HCs = healthy controls, IBS = irritable bowel syndrome, BMI = body mass index, HAD = hospital anxiety & depression, ETI = early trauma
inventory VSI = visceral sensitivity index Add all of the other clinical traits
doi:10.1371/journal.pone.0135910.t003
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symptom severity, EALs, and personality traits. Within the IBS patient group, those who were
homozygous for the major allele of theADRA1D SNP rs1556832 had higher IBS symptom severity
(i.e. overall severity, abdominal pain, bloating, and usual severity) compared to those who were
heterozygous or homozygous for the minor allele after adjusting for race and sex (p = 0.010).
Association of Catecholaminergic SNPs with Regional Brain Structural
Changes
Based on our above findings, we determined brain structural changes correlated with: 1)
ADRAβ2 SNP rs1042717 with and without taking sexual abuse score into account, 2) COMT
SNP rs174697 with and without taking emotional abuse score into account, and 3) ADRA1D
SNP rs1556832 in IBS. All brain regions with significant associations with catecholaminergic
SNPs are shown in Fig 3 The homozygous major allele ADRAβ2 rs1042717 genotype was asso-
ciated with decreases in the CT of the primary interoceptive cortex (left posterior insula) in the
presence of increasing sexual abuse scores (q = 0.004). On the other hand, the homozygous
and heterozygous ADRAβ2 rs1042717 minor allele genotypes were associated with decreases in
left putamen volume in the presence of increasing sexual abuse scores (q = 0.029). Regardless
of disease status or COMT SNP rs174697 genotype, increasing emotional abuse scores were
associated with increases in the CT of the left postcentral gyrus (primary somatosensory cor-
tex) (q = 0.042). In IBS patients only, the homozygous ADRA1D SNP rs1556832 major allele
genotype was associated with increases in the volume of the somatosensory regions (left post-
central [q = 0.022], the left precentral gyrus [q = 0.045]), and the right hippocampus (an affec-
tive region [q = 0.009]).
Table 4. Prevalence of Catecholaminergic Genotypes in IBS Patients and Healthy Controls.
SNP (Gene) Healthy Controls IBS Patients
rs1556832 (ADRA1D) C/C C/T T/T No Call C/C C/T T/T No Call
166 (43.6%) 159 (41.7%) 51 (13.4%) 5 (1.3%) 93 (33.5%) 134 (48.2%) 47 (16.9%) 4 (1.4%)
rs946188 (ADRA1D) A/A A/G G/G No Call A/A A/G G/G No Call
191 (50.1%) 162 (42.5%) 20 (5.2%) 8 (2.1%) 140 (50.4%) 118 (42.4%) 11 (4%) 9 (3.2%)
rs1432622 (ADRAβ2) C/C C/T T/T No Call C/C C/T T/T No Call
164 (43%) 161 (42.3%) 50 (13.1%) 6 (1.6%) 106 (38.1%) 128 (46%) 40 (14.4%) 4 (1.4%)
rs2400707 (ADRAβ2) G/G A/G A/A No Call G/G A/G A/A No Call
164 (43%) 161 (42.3%) 51 (13.4%) 5 (1.3%) 106 (38.1%) 129 (46.4%) 41 (14.7%) 2 (0.7%)
rs1042717 (ADRAβ2) G/G A/G A/A No Call G/G A/G A/A No Call
164 (43%) 161 (42.3%) 51 (13.4%) 5 (1.3%) 106 (38.1%) 129 (46.4%) 41 (14.7%) 2 (0.7%)
rs1042713 (ADRAβ2) G/G A/G A/A No Call G/G A/G A/A No Call
120 (31.5%) 165 (43.3%) 84 (22%) 12 (3.1%) 95 (34.2%) 123 (44.2%) 47 (16.9%) 13 (4.7%)
rs1800497 (ANKK1) C/C C/T T/T No Call C/C C/T T/T No Call
192 (50.4%) 148 (38.8%) 36 (9.4%) 5 (1.3%) 159 (57.2%) 93 (33.5%) 24 (8.6%) 2 (0.7%)
rs6269 (COMT) A/A A/G G/G No Call A/A A/G G/G No Call
171 (44.9%) 158 (41.5%) 46 (12.1%) 6 (1.6%) 107 (38.5%) 129 (46.4%) 38 (13.7%) 4 (1.4%)
rs4680 (COMT) G/G A/G A/A No Call G/G A/G A/A No Call
128 (33.6%) 181 (47.5%) 68 (17.8%) 4 (1%) 98 (35.3%) 111 (39.9%) 59 (21.2%) 10 (3.6%)
rs174697 (COMT) G/G A/G A/A No Call G/G A/G A/A No Call
250 (65.6%) 107 (28.1%) 19 (5%) 5 (1.3%) 219 (78.8%) 52 (18.7%) 6 (2.2%) 1 (0.4%)
rs6280 (DRD3) T/T C/T C/C No Call T/T C/T C/C No Call
142 (37.3%) 169 (44.4%) 66 (17.3%) 4 (1%) 107 (38.5%) 123 (44.2%) 44 (15.8%) 4 (1.4%)
doi:10.1371/journal.pone.0135910.t004
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To determine the potential influence of anxiety and depression symptoms on the observed
results, additional covariate analyses were performed. When controlling for depression and
anxiety scores, all differences were maintained for the ADRAB2 rs1042717 SNP on the cortical
thickness for the left posterior insula and the volume of the left putamen. When controlling for
depression and anxiety scores, the differences for the COMT SNP rs174697 on the cortical
thickness for the left postcentral gyrus remained significant. However, in IBS patients only,
when controlling for depression score the difference for the ADRA1D SNP rs1556832 on the
volume of the left hippocampus was no longer significant. When controlling for anxiety score
in IBS patients only, the difference for the ADRA1D SNP rs1556832 on all the initial findings
remained significant.
Correlation of Morphological Measures with GI Symptoms
Cortical thickness of the left somatosensory cortex (postcentral gyrus) was positively correlated
with usual severity of IBS symptoms (r = 0.258, q = 0.023). Although there were other cortical
thickness and grey matter volume measures in brain regions other than the somatosensory cor-
tex (postcentral gyrus) that were significantly correlated with GI symptoms, they did not sur-
vived corrections for multiple comparisons.
Discussion
We aimed to test the hypothesis that genetic and environmental factors interact to influence
IBS status, GI symptomology and brain structure in a large, well phenotyped cohort of 659 IBS
and HC subjects. This study showed that catecholaminergic SNPs were associated with IBS
Fig 1. The Presence of the Minor Allele in the ADRAβ2 rs1042717 GeneWhen Interacted with
Increasing Sexual Scores is Protective Against an IBS Diagnosis. ADRAβ2 rs1042717 (A/G or A/A) in
the presence of an elevated ETI-SR sexual abuse score results in a lower likelihood of IBS (interaction term
OR = 0.73, 95% CI: 0.55–0.98, p = 0.039). Odds ratios and 95%CIs for a unit increase in ETI-SR sexual
abuse score are reported from separate logistic regression models run within each genetic subgroup.
doi:10.1371/journal.pone.0135910.g001
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symptom severity and grey matter alterations in specific brain regions involved in sensory pro-
cessing and affect regulation (Table 5). Despite the fact that altered catecholaminergic signaling
is commonly associated with many chronic pain conditions and that EALs are common envi-
ronmental factors associated with IBS, to our knowledge, this is the first demonstration of
interactions of these factors in influencing symptom related morphological brain changes in a
large cohort of IBS patients.
Effect of Catecholaminergic SNPs on IBS Diagnosis and Symptoms
We did not find any statistically significant relationships between the catecholaminergic SNPs
and the presence of IBS with or without the interaction with EALs after adjusting for multiple
comparisons. However, the α-adrenergic SNP, ADRA1D rs1556832, was significantly associ-
ated with GI symptom severity. There is minimal data that describes the role of ADRA1D
receptor activity in the GI tract. However, a previous study demonstrated that the genotype fre-
quencies of ADRA1D and ADRAβ2 SNP were associated with bladder pain syndrome/intersti-
tial cystitis (BPS/IC), a chronic visceral pain disorder which often coexists with IBS[9] and
which shows similar brain changes as IBS (unpublished observations). In addition, ADRA1D
tissue expression was increased in patients with bladder outlet obstruction and in patients with
lower urinary symptoms who had increased bladder sensitivity. [44] Thus, this receptor is
thought to play a role in sensory afferent processing, and in contractile activity.[44] Further
studies are needed to determine if ADRA1D receptors have a similar effect on colonic function
and if they have a pathophysiologic role in IBS.
Fig 2. The Presence of the Minor Allele in theCOMT rs174697 GeneWhen Interacted with Increasing
Emotional Scores is Protective Against an IBS Diagnosis.COMT SNP rs174697 (A/G or A/A) in the
presence of an elevated ETI-SR emotional abuse score results in a lower likelihood of IBS than the G/G
(major allele) genotype (interaction term OR = 0.76, 95% CI: 0.60–0.99, p = 0.041). Odds ratios and 95%CIs
for a unit increase in ETI-SR emotional abuse score are reported from separate logistic regression models
run within each genetic subgroup.
doi:10.1371/journal.pone.0135910.g002
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Effect of EALs on Brain Structure
We found that regardless of disease status or COMT SNP rs174697 genotype, increasing emo-
tional abuse scores were associated with increases in the CT of the primary somatosensory cor-
tex.[45] Increased thickness of somatosensory cortex has been reported in several chronic pain
conditions, including IBS, BPS/IC, TMD, migraine, and chronic back pain.[13,46–48] The
mechanisms underlying this increase are incompletely understood but may include increased
Fig 3. Brain Regions with Significant Associations with Catecholaminergic SNPs. The increase in cortical thickness of left posterior insula was
demonstrated for the homozygous major allele ADRAβ2 rs1042717 genotype in the presence of increasing sexual abuse scores (q = 0.004). The decrease in
the volume of the left putamen was demonstrated for the homozygous and heterozygous ADRAβ2 rs1042717 minor allele genotypes in the presence of
increasing sexual abuse scores (q = 0.029). An increase in the cortical thickness of the left postcentral gyrus was demonstrated in the presence of increasing
emotional abuse scores, regardless of disease status or COMT SNP rs174697 genotype (q = 0.042). Increases in the volumes of left postcentral gyrus
(q = 0.022), left precentral gyrus (q = 0.045), and right hippocampus (q = 0.009) were demonstrated for the homozygous ADRA1D SNP rs1556832 major
allele genotype in IBS patients. The association of ADRA1D SNP rs1556832 with the right hippocampus volume was not significant after controlling for HAD
depression scores.
doi:10.1371/journal.pone.0135910.g003
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regional growth factor release in response to continuous sensory input.[46,49–51] Alterna-
tively, one study showed that neuroplastic changes in the somatosensory cortex were present in
HCs who had increased sensitivity to experimental pain stimuli, in the absence of pain disor-
ders. Furthermore, sensitivity to acute pain and heat pain stimuli was positively correlated with
the thickness of the somatosensory cortex,[52,53] suggesting that this cortical alteration may
be a risk factor for the development of chronic pain disorders.
A positive history of EALs is associated with an increased likelihood of developing IBS and
other chronic pain conditions,[54] as well as, increased pain perception and sensitivity.[55] In
addition, GM alterations have been reported in adults with a history of EALs, including larger
volumes in the amygdala and reduced volumes in the prefrontal and anterior cingulate cortices,
hippocampus, and cerebellum.[56–59] Even though alternative explanations are possible, these
structural findings may reflect the compromised corticolimbic inhibition thought to result
from early trauma.[3] Consistent with these findings, we recently reported EAL-associated
changes in the connectivity of a saliency network in the brain that included viscero- and
somatosensory regions.[60] Furthermore, as both a history of EALs and cortical somatosensory
increases have been observed in IBS previously, the observed correlation between EAL scores
and cortical thickness found in this study provides a possible mechanistic insight into these
brain changes.
Interaction of Catecholaminergic SNPs, EALs and Diagnosis on Brain
Structure
Individuals carrying the ADRAβ2 SNP rs1042717 major allele in a homozygous state had a
higher likelihood of having IBS if they had a higher early life sexual abuse score, compared to
those with a dominant genotype (i.e., at least one copy of the minor allele). Although this was
not statistically significant after adjusting for multiple comparisons, this is consistent with our
finding that the dominant genotype has protective effects against decreases in both the volume
Table 5. Summary of Main Findings.
Gene SNP Association with IBS +/- EALs Association with
Symptoms
Associated Brain Regions
COMT rs4680
(Val158Met)
- - -
rs6269 - - -
rs174697 HM with increasing emotional abuse
score increased likelihood of IBS
(p = 0.041 uncorrected)
- HM, Hm &He = increased CT of left postcentral
gyrus (All with increasing emotional abuse scores)
ADRAβ2 rs1432622 - - -
rs2400707 - - -
rs1042717 HM with increasing sexual abuse
score increased likelihood of IBS
(p = 0.039 uncorrected)
- HM = Decreased CT of left posterior insula, Hm &
He = Decreased left putamen volume (All with
increasing sexual abuse scores)
rs1042713 - - -
ADRA1D rs1556832 - HM individuals had higher
IBS symptom severity
(p = 0.010)
HM = increased volume of left postcentral gyrus, left
precentral gyrus, and the right hippocampus in IBS
patients
rs946188 - - -
ANKK1 rs1800497 - - -
DRD3 rs6280 - - -
HM = homozygous major, Hm = homozygous minor, He = heterozygous, CT = cortical thickness
doi:10.1371/journal.pone.0135910.t005
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of the left putamen (bidirectional connection with cortical control regions) and CT of the pri-
mary interoceptive cortex (pINS), with increasing sexual abuse scores in IBS patients.
Interestingly, repeated stress in rodents has been shown to enhance peripheral visceral noci-
ceptive signaling via adrenergic receptors.[61–63] For example, elevated circulating epineph-
rine (acting on β2 adrenergic receptors) can signal directly to colonic dorsal root ganglion
neurons, resulting in visceral hyperexcitability and hyperalgesia to repeated stress.[61] In
another study, three haplotypes of the ADRAβ2 receptor gene, which accounted for 98% of the
study population (n = 386), were found to predict hyper- or hypo-functioning states of the
ADRAβ2 receptor, both of which resulted in an increased incidence of temporomandibular
joint disorder.[7] This study suggests that genetic variability may predispose individuals to
chronic pain disorders, a concept consistent with the current findings.
The homozygous ADRA1D SNP rs1556832 major allele genotype was associated with
increases in CT of somatosensory regions in IBS patients. Since this SNP was the only one that
correlated with GI symptom severity, it suggests that these brain changes in IBS may be
involved in viscerosensory processing or pain modulation.
Similar to the current findings, previous studies have shown that compared to HCs, IBS
patients have decreased volume of the putamen and decreased CT of the pINS,[12,13] and
these findings are similar to those found in other chronic pain conditions.[13,46–48,64] Studies
have also shown that in the presence of a history of EALs, neuroplastic decreases in other brain
regions are evident.[65] When viewed together with the relationship between somatosensory
cortex and EALs, the current findings suggest that the risk or resilience towards the negative
effects of EALs on some regional grey matter are determined by the interaction of early envi-
ronmental factors with genes and disease status.[66]
Preclinical studies have shown that alterations in the adrenergic and noradrenergic systems
play key roles in mediating physiological and behavioral responses in the brain in response to
EALs.[67] Perinatal stress, an established rodent model for EALs has been shown to result in
increased norepinephrine output from the locus coeruleus,[68,69] and increases in plasma nor-
epinephrine levels have been reported in IBS patients both at rest and under stressful condi-
tions.[69] Increased noradrenergic modulations of brain regions that are associated with the
regulation of emotion, fear, and anxiety have been reported.[70] One can speculate that the
observed interactions between catecholaminergic SNPs and EALs may determine the degree of
abnormal emotional arousal and related engagement of descending pain facilitatory pathways.
Predominant descending facilitation of spinal sensory transmission may in turn result in a
chronically enhanced ascending sensory input to sensory brain regions as previously suggested.
[12,13,52] Such a mechanism of chronically enhanced visceral hypersensitivity would be con-
sistent with the observed neuroplastic changes, the persistent hypervigilance towards GI sig-
nals,[3,69] and potentially explain the increased severity of GI symptoms seen in our study.[3]
Conclusions and Possible Clinical Implications
In IBS patients, catecholaminergic SNPs were associated with IBS symptom severity and struc-
tural changes in brain regions that are involved in sensory processing and affect regulation,
which have previously been described in IBS patients and in other comorbid pain conditions,
such as PBS/IC. If replicated in other samples, some of the observed regional grey matter
changes may represent endophenotypes, which are influenced by genetic and epigenetic factors
and contribute to the complex clinical phenotype. In that case, these endophenotypes should
be present in asymptomatic relatives of IBS patients, and may represent a vulnerability factor,
which increases the risk of developing IBS under physical (infections, inflammation) or psy-
chological stressors. The association of catecholaminergic SNPs with IBS with or without EALs
Catecholaminergic Polymorphisms in IBS
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did not meet statistical significance after accounting for multiple comparisons, and therefore
further studies in larger samples are needed. In addition, future studies in other functional pain
populations will be needed to determine if such endophenotypes are disease specific or repre-
sent a general risk factor, which predicts the development of chronic pain conditions.
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